JNJ-54861911 10 mg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Alzheimer DiseaseHealthy

Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

CompletedNCT01887535

Janssen Research & Development, LLCHealthy

Start: 2013-05-31End: 2013-12-31Updated: 2014-01-14

A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

CompletedNCT01978548

Janssen Research & Development, LLCAlzheimer Disease

Start: 2013-12-31End: 2015-04-30Updated: 2015-06-25

Related Papers

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Alzheimer s Research & Therapy2018-08-22106 citations